Skip to main content

Table 2 Eligibility to the procedure of CRS with HIPEC

From: Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons

Factors that interrupt the right treatment of CRS with HIPEC

N (%)

 

Old age

7 (21)

 

ECOG performance status

18 (53)

 

Invasion to numerous mesenteries

34 (100)

 

 Cancer that invade multiple organs (more than 3 organs)

5 (15)

 

 Cancer that invade more than 3 parts of liver parenchyma

10 (29)

 

 Cancer that invade the portal vein

16 (47)

 

 Cancer that invade a frozen pelvis

7 (21)

 

 Ureteral stricture

2 (6)

 

 Others

2 (6)

 

The number of factors that interrupt the right treatment of CRS with HIPEC

Mean (SD)

P

Surgeon’s age (n)

 < 50 (23)

2.41 ± 1.43

 

 > 50 (11)

2.81 ± 1.60

0.352

Volume of medical institution (n)

 University hospital (23)

2.42 ± 1.43

 

 Other hospital (11)

2.81 ± 1.60

0.488

Experience number of PSM (n)

 < 50 (20)

2.26 ± 1.49

 

 < 50 (14)

3.21 ± 1.31

0.079